880 Results for "

IFN-γ/STAT1/SLC7A11 axis

" in MedChemExpress (MCE) Product Catalog:
Products (880)

880 Results for "IFN-γ/STAT1/SLC7A11 axis" in MCE Product Catalog:

905
905 Publications Verification
Cat. No.: HY-15763
CAS No.: 571203-78-6
Purity:  99.62%
Research Areas:  

Cancer

Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation [1] .
loading...
    loading...
119
119 Cited Publications
Cat. No.: HY-B0069
CAS No.: 21679-14-1
Synonyms: F-ara-A; NSC 118218
Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes [1] .
loading...
    loading...
103
103 Cited Publications
Cat. No.: HY-40354
CAS No.: 477600-75-2
Synonyms: Tasocitinib; CP-690550
Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [1] .
loading...
    loading...
103
103 Cited Publications
Cat. No.: HY-40354A
CAS No.: 540737-29-9
Synonyms: Tasocitinib citrate; CP-690550 citrate
Tofacitinib citrate (Tasocitinib citrate) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib citrate blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib citrate can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [1] .
loading...
    loading...
85
85 Cited Publications
Cat. No.: HY-P7025
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IFNG; IMD69; Interferon Gamma; IFG; IFN-Gamma; IFI; Immune Interferon
Species:  
Human
Source:  
E. coli
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-P7071
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IFNG; IMD69; Interferon Gamma; IFG; IFN-Gamma; IFI; Immune Interferon
Species:  
Mouse
Source:  
E. coli
loading...
    loading...
46
46 Cited Publications
Cat. No.: HY-14644
CAS No.: 541550-19-0
Purity:  99.80%
Synonyms: STA 5326; LAM-002A free base; AIT-101
Research Areas:  

Inflammation/Immunology Cancer

Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively [1]. Apilimod is a potent and highly selective PIKfyve inhibitor.
loading...
    loading...
46
46 Cited Publications
Cat. No.: HY-14644A
CAS No.: 870087-36-8
Purity:  99.83%
Synonyms: STA 5326 mesylate; LAM-002A; AIT-101 mesylate
Research Areas:  

Inflammation/Immunology Cancer

Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively [1]. Apilimod is a potent and highly selective PIKfyve inhibitor.
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-112288
CAS No.: 432001-19-9
Purity:  99.90%
Synonyms: TTI-101
C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia [1] .
loading...
    loading...
36
36 Cited Publications
Cat. No.: HY-117287
CAS No.: 1609392-27-9
Purity:  99.87%
Synonyms: BMS-986165
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus [1] .
loading...
    loading...
23
23 Cited Publications
Cat. No.: HY-16997
CAS No.: 1334298-90-6
Synonyms: INCB039110
Target:  

JAK STAT

Research Areas:  

Inflammation/Immunology Cancer

Itacitinib (INCB039110) is an orally active selective inhibitor of JAK1 with an IC50 value of 2 nM for human JAK1. Itacitinib inhibits IFN-γ-mediated phosphorylation of STAT1 and downstream pro-inflammatory signaling pathways. Itacitinib reduces the frequency and number of splenic neutrophils in mouse models, downregulates the levels of pro-inflammatory cytokines and chemokines, and inhibits pro-inflammatory gene expression pathways. Itacitinib improves survival rate and clinical scores in mouse models of hemophagocytic lymphohistiocytosis (HLH), and also suppresses metastasis in NSCLC models with high Rab1A expression. Itacitinib can be used for research on hemophagocytic lymphohistiocytosis and non-small cell lung cancer [1] .
loading...
    loading...
23
23 Cited Publications
Cat. No.: HY-16997A
CAS No.: 1334302-63-4
Synonyms: INCB039110 adipate
Target:  

JAK STAT

Research Areas:  

Inflammation/Immunology Cancer

Itacitinib adipate (INCB039110 adipate) is an orally active JAK1-selective inhibitor. Itacitinib adipate inhibits IFN-γ-mediated phosphorylation of STAT1 and downstream pro-inflammatory signaling pathways. Itacitinib adipate reduces the frequency and number of splenic neutrophils in mouse models, downregulates the levels of pro-inflammatory cytokines and chemokines, and inhibits pro-inflammatory gene expression pathways. Itacitinib adipate improves survival rate and clinical scores in mouse models of hemophagocytic lymphohistiocytosis (HLH), and also suppresses metastasis in NSCLC models with high Rab1A expression. Itacitinib adipate can be used for research on hemophagocytic lymphohistiocytosis and non-small cell lung cancer [1] .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15193
CAS No.: 1181770-72-8
Purity:  99.94%
EMD638683 is an orally active SGK1 inhibitor with an IC50 of 3 μM. EMD638683 exhibits strong inhibition against SGK1, moderate inhibition against SGK2 and SGK3, and shows excellent selectivity for other AGC kinase family members. EMD638683 has antihypertensive activity by inhibiting SGK1, and independently of the blood pressure-lowering effect, it effectively prevents heart inflammation and fibrosis caused by hypertension by inhibiting the cardiac NLRP3 inflammation body/ IL-1β axis. EMD638683 promotes apoptosis of colon cancer cells and sensitizes radiotherapy. EMD638683 (S-Form) can be used in research related to hypertension, hypertensive heart damage, and colon cancer [1] .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-19744
CAS No.: 2437475-16-4
Target:  

MyD88

Research Areas:  

Inflammation/Immunology

T6167923 is a selective inhibitor of MyD88-dependent signaling pathways. T6167923 directly binds to Toll/IL1 receptor (TIR) domain of MyD88 and disrupts MyD88 homodimeric formation. T6167923 inhibits NF-κB driven Staphylococcus enterotoxin AP (SEAP) activity, and improves anti-inflammatory activity with IC50s of 2.7 μM, 2.9 μM, 2.66 μM and 2.66 μM for IFN-γ, IL-1β, IL-6 and TNF-α, respectively [1] .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-144806
CAS No.: 3033069-84-7
Purity:  99.64%
Target:  

PI3K Akt Apoptosis

Research Areas:  

Cancer

PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis [1].
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-112005
CAS No.: 4004-05-1
Purity:  98.80%
Synonyms: Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine
DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease [1] .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-15136
CAS No.: 193275-84-2
Purity:  99.60%
Synonyms: Sch66336
Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria [1] .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-W013523
CAS No.: 65182-56-1
Target:  

STAT JAK HSV

Research Areas:  

Infection Cancer

2-NP is a selective enhancer of STAT1 transcription. 2-NP can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells [1].
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-P80935
Synonyms: CCBR1; Cysteine/glutamate transporter; SLC7A11; solute carrier family 7; xCT

Host:  

Rabbit

Application:  

WB, IP

Reactivity:  

Human, Mouse

loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-107429
CAS No.: 1622902-68-4
Purity:  99.26%
Synonyms: PF-04965842
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease [1].
loading...
    loading...